- 期刊
Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease
延伸閱讀
- 楊盈盈（2022）。The Clinical Courses, Risk Factors, and Prognosis of Non-Alcoholic Fatty Liver Disease。台灣醫學，26(3)，322-327。https://doi.org/10.6320/FJM.202205_26(3).0006
- Lee, Y. H., Wu, Y. J., Liu, C. C., Hou, C. J. Y., Yeh, H. I., Tsai, C. H., Shih, S. C., & Hung, C. L. (2011). The Severity of Fatty Liver Disease Relating to Metabolic Abnormalities Independently Predicts Coronary Calcification. Radiology Research and Practice, 2011(), 89-96. https://doi.org/10.1155/2011/586785
- 陳瑋成、楊宜青、吳晉祥、黃盈翔、張尹凡、盧豐華、張智仁（2012）。The Correlates of Nonalcoholic Fatty Liver Disease in Subjects with Normal Liver Function。台灣家庭醫學雜誌，22(1)，25-33。https://doi.org/10.7023/TJFM.201203.0025
- Liu, S., Qu, X., Liu, F., & Wang, C. (2014). Pentraxin 3 as a Prognostic Biomarker in Patients with Systemic Inflammation or Infection. Mediators of Inflammation, (2014-4), 193-201. https://doi.org/10.1155/2014/421429
- Wang, N., Kong, R., Luo, H., Xu, X., & Lu, J. (2017). Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease. PPAR Research, 2017(), 1-8-017. https://doi.org/10.1155/2017/6561701